- Home
- BGI vs BIVI Comparison
BGI vs BIVI Comparison
Compare BGI & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- BIVI
- Stock Information
- Founded
- BGI 1879
- BIVI 2013
- Country
- BGI Canada
- BIVI United States
- Employees
- BGI N/A
- BIVI N/A
- Industry
- BGI
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- BIVI Health Care
- Exchange
- BGI Nasdaq
- BIVI Nasdaq
- Market Cap
- BGI 15.7M
- BIVI 15.0M
- IPO Year
- BGI 2005
- BIVI N/A
- Fundamental
- Price
- BGI $0.61
- BIVI $1.79
- Analyst Decision
- BGI
- BIVI
- Analyst Count
- BGI 0
- BIVI 0
- Target Price
- BGI N/A
- BIVI N/A
- AVG Volume (30 Days)
- BGI 160.9K
- BIVI 333.3K
- Earning Date
- BGI 07-25-2025
- BIVI 09-29-2025
- Dividend Yield
- BGI N/A
- BIVI N/A
- EPS Growth
- BGI N/A
- BIVI N/A
- EPS
- BGI N/A
- BIVI N/A
- Revenue
- BGI $124,446,731.00
- BIVI N/A
- Revenue This Year
- BGI N/A
- BIVI N/A
- Revenue Next Year
- BGI N/A
- BIVI N/A
- P/E Ratio
- BGI N/A
- BIVI N/A
- Revenue Growth
- BGI N/A
- BIVI N/A
- 52 Week Low
- BGI $0.57
- BIVI $1.52
- 52 Week High
- BGI $2.95
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- BGI 22.36
- BIVI 19.29
- Support Level
- BGI $0.82
- BIVI $1.52
- Resistance Level
- BGI $0.78
- BIVI $7.75
- Average True Range (ATR)
- BGI 0.08
- BIVI 0.65
- MACD
- BGI -0.02
- BIVI -0.49
- Stochastic Oscillator
- BGI 10.54
- BIVI 3.92
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.